EGFR and adenocarcinoma: Immunohistochemical results showed EGFR positivity in 8.7% of GERD patients (11/127), 25% of BE patients (6/24), and 46.5% of adenocarcinoma patients (20/43), with statistically significant differences among the groups (p = 0.0001).